Indication
HR+/HER2- Metastatic Breast Cancer
The HR+/HER2- Metastatic Breast Cancer pipeline: 102 tracked drugs, 27 approved for this indication.
27 approved / phase 430 Phase 31 Phase 2/310 Phase 221 Phase 1/213 Phase 1
Compare the share prices of listed companies in HR+/HER2- Metastatic Breast Cancer →
Total attributable cost
$22.7B
$214,664/patient
Drug spend
$2.4B
$22,727/patient
11% of total cost is drugs
Metastatic (stage IV), de novo and recurrent · US